NCT01794702View on ClinicalTrials.gov

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 20, 2013

Primary Completion Date

January 11, 2018

Study Completion Date

January 11, 2018

Conditions
Leukemia
Interventions
DRUG

Decitabine

Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)

DRUG

Idarubicin

Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)

DRUG

Cytarabine

Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)

DRUG

Clofarabine

"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01794702 - Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | Biotech Hunter | Biotech Hunter